RECURSION PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
RECURSION PHARMACEUTICALS, INC. (RXRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $19.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $19.50M, a 25.47% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $22.21M, a 38.39% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $23.76M, a 22.81% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $25.24M, a 38.31% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $111.22M, a 36.16% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $81.69M, a 52.68% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $53.50M, a 91.71% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $27.91M, a 88.04% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.50M 10-Q · filed 2026-08-05 | $41.71M 10-Q · filed 2026-08-05 | $65.48M derived: sum of 3 quarters · filed 2026-08-05 | $90.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $22.21M 10-Q · filed 2026-05-06 | $45.98M derived: sum of 2 quarters · filed 2026-05-06 | $71.22M derived: sum of 3 quarters · filed 2026-05-06 | $97.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $23.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $49.01M derived: sum of 2 quarters · filed 2026-02-25 | $75.17M derived: sum of 3 quarters · filed 2026-08-05 | $111.22M 10-K · filed 2026-02-25 |
| 2025-09-30 | $25.24M 10-Q · filed 2025-11-05 | $51.40M derived: sum of 2 quarters · filed 2026-08-05 | $87.46M 10-Q · filed 2025-11-05 | $118.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $26.16M 10-Q · filed 2026-08-05 | $62.22M 10-Q · filed 2026-08-05 | $93.00M derived: sum of 3 quarters · filed 2026-08-05 | $111.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $36.06M 10-Q · filed 2026-05-06 | $66.84M derived: sum of 2 quarters · filed 2026-05-06 | $85.09M derived: sum of 3 quarters · filed 2026-05-06 | $101.62M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $30.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $49.04M derived: sum of 2 quarters · filed 2026-02-25 | $65.56M derived: sum of 3 quarters · filed 2026-02-25 | $81.69M 10-K · filed 2026-02-25 |
| 2024-09-30 | $18.25M 10-Q · filed 2025-11-05 | $34.78M derived: sum of 2 quarters · filed 2025-11-05 | $50.90M 10-Q · filed 2025-11-05 | $66.99M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $16.52M 10-Q · filed 2025-08-05 | $32.65M 10-Q · filed 2025-08-05 | $48.74M derived: sum of 3 quarters · filed 2026-02-25 | $65.53M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $16.13M 10-Q · filed 2025-05-05 | $32.21M derived: sum of 2 quarters · filed 2026-02-25 | $49.01M derived: sum of 3 quarters · filed 2026-02-25 | $60.82M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $16.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $32.88M derived: sum of 2 quarters · filed 2026-02-25 | $44.69M derived: sum of 3 quarters · filed 2026-02-25 | $53.50M 10-K · filed 2026-02-25 |
| 2023-09-30 | $16.79M 10-Q · filed 2024-11-06 | $28.60M derived: sum of 2 quarters · filed 2024-11-06 | $37.42M 10-Q · filed 2024-11-06 | $45.11M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $11.81M 10-Q · filed 2024-08-08 | $20.63M 10-Q · filed 2024-08-08 | $28.32M derived: sum of 3 quarters · filed 2025-02-28 | $37.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $8.81M 10-Q · filed 2024-05-09 | $16.51M derived: sum of 2 quarters · filed 2025-02-28 | $25.42M derived: sum of 3 quarters · filed 2025-02-28 | $31.09M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $16.60M derived: sum of 2 quarters · filed 2025-02-28 | $22.28M derived: sum of 3 quarters · filed 2025-02-28 | $27.91M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.91M 10-Q · filed 2023-11-09 | $14.58M derived: sum of 2 quarters · filed 2023-11-09 | $20.21M 10-Q · filed 2023-11-09 | $24.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $5.67M 10-Q · filed 2023-08-08 | $11.31M 10-Q · filed 2023-08-08 | $15.65M derived: sum of 3 quarters · filed 2024-02-29 | $19.01M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $5.63M 10-Q · filed 2023-05-08 | $9.97M derived: sum of 2 quarters · filed 2024-02-29 | $13.34M derived: sum of 3 quarters · filed 2024-02-29 | $18.65M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.70M derived: sum of 2 quarters · filed 2024-02-29 | $13.02M derived: sum of 3 quarters · filed 2024-02-29 | $14.84M 10-K · filed 2024-02-29 |
| 2021-09-30 | $3.36M 10-Q · filed 2022-11-08 | $8.68M derived: sum of 2 quarters · filed 2022-11-08 | $10.50M 10-Q · filed 2022-11-08 | $11.59M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $5.32M 10-Q · filed 2022-08-09 | $7.14M 10-Q · filed 2022-08-09 | $8.23M derived: sum of 3 quarters · filed 2023-02-27 | $9.25M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.82M 10-Q · filed 2022-05-10 | $2.91M derived: sum of 2 quarters · filed 2023-02-27 | $3.94M derived: sum of 3 quarters · filed 2023-02-27 | $4.83M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.11M derived: sum of 2 quarters · filed 2023-02-27 | $3.01M derived: sum of 3 quarters · filed 2023-02-27 | $4.29M 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.02M 10-Q · filed 2021-11-10 | $1.92M derived: sum of 2 quarters · filed 2021-11-10 | $3.20M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $892.00K 10-Q · filed 2021-08-13 | $2.18M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $1.29M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.39M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |